Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Duloxetine (Generic Health) TM
Active ingredients: duloxetine
What it is used for
Duloxetine Hydrochloride is indicated for the following:,-Treatment of major depressive disorder (MDD). ,-Treatment of generalised anxiety disorder (GAD).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Store in Original Container
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Size '3' Capsules with dark blue cap & white body, imprinted with "DU" in white ink on cap & "30" in black ink on body,containing six mini tablets.
Food interactions
For the active ingredient duloxetine
- Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%.
- People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity.
- Take without regard to meals.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient duloxetine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Diabetic neuropathy - Better Health Channel
Diabetes is the most common cause of neuropathy
Read more on Better Health Channel website
Fibromyalgia - Pain Conditions - painHEALTH
Learn about Fibromyalgia as a muscularskeletal pain condition to identify how you can approach Fibromyalgia in your co-management treatment plan
Read more on painHEALTH website
Neuropathic pain: current definition and review of drug treatment | Australian Prescriber
The definition of neuropathic pain has changed and opioids have been relegated to third-line therapy.
Read more on Australian Prescriber website
Neuropathy in diabetes - myDr.com.au
Neuropathy in diabetes (also called diabetic nerve damage or diabetic neuropathy) is temporary or permanent damage to nerve tissue in people with diabetes mellitus. Symptoms depend on which nerves are
Read more on myDr website
Neuropathic pain - myDr.com.au
Find out all about neuropathic pain (nerve pain), which is usually described as a shooting, stabbing or burning pain, with myDr.com.au.
Read more on myDr website
Peripheral Neuropathy | Leukaemia Foundation
Peripheral Neuropathy is commonly experience with myeloma, and is a broad term that describes any changes to the nerves and their function in the body's extremities.
Read more on Leukaemia Foundation website
Prescribing wellness:comprehensive pain managementoutside specialist services | Australian Prescriber
Opioids have important roles in the time-limited treatment of acute and cancer pain, end-of-lifepain or dyspnoea,...
Read more on Australian Prescriber website
Top results
Duloxetine versus other antidepressive agents for depression | Cochrane
Although pharmacological and psychological interventions are both effective for major depression, antidepressant drugs remain the mainstay of treatment in moderate to severe major depression. During the last 20 years, newer compounds (such as selective serotonin reuptake inhibitors and dual action agents such as serotonin noradrenalin reuptake inhibitors) have progressively become the most commonly prescribed antidepressants. Duloxetine hydrochloride, one of the most recent antidepressants introduced in the market, is a selective serotonin noradrenergic reuptake inhibitor for oral administration. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of duloxetine in comparison with all other antidepressants in the acute-phase treatment of major depression. Sixteen randomised controlled trials (5735 participants) were included. Duloxetine was not more effective than some other new antidepressant agents in the acute-phase treatment of major depression, and it was less well tolerated than escitalopram and venlafaxine as more patients allocated to duloxetine withdrew treatment before study end. However, due to the limited number of studies per comparison these results should be interpreted with caution.
Read more on Cochrane (Australasian Centre) website
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Cochrane
Read more on Cochrane (Australasian Centre) website
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Cochrane
Read more on Cochrane (Australasian Centre) website
Second-generation antipsychotic drugs for major depressive disorder | Cochrane
This review found 28 studies on five second-generation antipsychotic drugs (amisulpride, aripiprazole, olanzapine, quetiapine and risperidone) comparing the effects of the drugs alone or adding them or placebo to antidepressants for major depressive disorder and dysthymia. There is evidence that amisulpride might lead to symptom reduction in dysthymia, while no important differences were seen for major depression. There is limited evidence that aripiprazole leads to symptom reduction when added to antidepressants. Olanzapine had no beneficial effects for treatment of depression when compared to antidepressants or compared to placebo but there was limited evidence for the benefits of olanzapine as additional treatment. Data on quetiapine indicated beneficial effects for quetiapine alone or as additional treatment when compared to placebo; data on quetiapine versus duloxetine did not show beneficial effects in terms of symptom reduction for either group, but quetiapine treatment was less well tolerated. The data, however, are very limited. Slight benefits of risperidone as additional treatment, in terms of symptom reduction, are also based on a rather small number of randomised participants. Generally, treatment with second-generation antipsychotic drugs was associated with worse tolerability, mainly due to sedation, weight gain or laboratory values such as prolactin increase.
Read more on Cochrane (Australasian Centre) website
Second-generation antidepressants for winter depression | Cochrane
Seasonal affective disorder (winter depression) is a type of depression that recurs in the autumn and lasts until the spring. It is similar to regular depression except sufferers are usually very tired and have an increase in their appetite. It is more common in countries with few daylight hours in winter. One of the mainstays of treatment for all depression, including winter depression, are second-generation antidepressants (SGAs) such as selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs). It is not clear how well these drugs work for winter depression and how they compare to each other or to other types of therapy such as light therapy.
Read more on Cochrane (Australasian Centre) website
Prescribing psychotropic drugs to adults with an intellectual disability | Issue 4 | Volume 39 | Australian Prescriber
Mental illness is common in people with intellectual disability. They may also have physical health problems which can affect their mental state.
Read more on Australian Prescriber website
Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women | Cochrane
Read more on Cochrane (Australasian Centre) website
Switching and stopping antidepressants | Issue 3 | Volume 39 | Australian Prescriber
Switching people from one antidepressant to another is commonly needed but can cause drug withdrawal symptoms, drug interactions and relapse in depression....
Read more on Australian Prescriber website
Treatment of fibromyalgia | Australian Prescriber
Find out what approaches work best for patients with fibromyalgia.
Read more on Australian Prescriber website
Managing osteoarthritis | Issue 4 | Volume 38 | Australian Prescriber
Management of osteoarthritis should be based on a combination of non-drug and drug treatments targeted towards prevention, modifying risk and disease...
Read more on Australian Prescriber website
